Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Eli Lilly and Co., which cemented its place ... tumors that is currently in a Phase 1/2 clinical trial. Lilly (NYSE: LLY) will pay Scorpion up to $2.5 billion in cash for the drug, including ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is ...

As part of the proposed terms, Eli Lilly would pay Boston-based Scorpion about $1bn up front followed by up to $1.5bn at a later date if certain performance milestones were met, according to three ...

If Eli Lilly continues to move lower, a bear put spread would be the best way to trade it. A bear put spread is a debit spread. That means we need to pay the premium to open the t ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Eli Lilly & Co. will pay as much as $2.5 billion in cash to acquire a cancer drug that Scorpion Therapeutics Inc. is testing in early and mid-stage trials. The purchase includes an unspecified upfront ...

A longtime pharmaceutical executive laments the woeful state of the industry and calls for new leadership to win back public ...

The 'big three' insulin producers Novo Nordisk, Eli Lilly, and Sanofi are being sued ... Hispanic white people - and much more likely to die as a result of complications. The complaint - which ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 465.16% and ...